Shots:
- Silence has reported topline P-II (SANRECO) trial results assessing divesiran (6mg/kg, SC, Q6W or Q12W) vs PBO in 48 phlebotomy-dependent patients with polycythemia vera (PV); P-III PV trial for Q12W dosing to initiate in H1’27
- Trial met its 1EP, with significantly more PV pts responding to divesiran vs PBO (88% vs 19%). Response was defined as no phlebotomy & HCT <45% during Wks. 18-36; rates were 93.8% with Q6W & 81.3% with Q12W dosing
- The key 2EP was also met during Wks. 0-36, with divesiran significantly reducing mean phlebotomies per patient (0.2 vs 2.1). Divesiran also improved hematocrit control, ferritin & other iron markers, & PROs measured by MPN-SAF TSS
Ref: Businesswire | Image: Silence Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
